medigraphic.com
ISSN 0188-2198 (Impreso)

2000, Número 4

<< Anterior Siguiente >>

Rev Mex Cardiol 2000; 11 (4)


Anticoagulantes

Navarro RJ, Valencia SJS, Abundes VA, Betancourt HL

Idioma: Español
Referencias bibliográficas: 34
Paginas: 304-313
Archivo PDF: 120.96 Kb.


RESUMEN

El papel de la trombina en el proceso de coagulación es considerado de gran importancia. Esta enzima, cuya acción fisiológica es evitar la extravasación de sangre, posterior al daño vascular y promover la reparación del tejido, también tiene una manifestación adversa: la trombosis.Los anticoagulantes tienen un lugar importante en la terapéutica de diversas patologías, principalmente en la isquémica y vascular cardiacas. Durante mucho tiempo sólo se contaba con la heparina estándar y las cumarinas (warfarina), que aunque se constituían como medicamentos de elección para la terapéutica de las enfermedades vasculares, conllevan efectos colaterales adversos. Sin embargo, en un futuro existe la posibilidad de sustituirlos por fármacos específicos para inhibir la trombosis, ya que estos medicamentos ofrecen resultados más seguros para lograr la prevención y propagación de trombos en las enfermedades cardiovasculares. Por ejemplo, el tratamiento indicado en cardiopatía isquémica es la trombólisis más ácido acetilsalicílico más heparina, no sin antes realizar un análisis cuidadoso del paciente.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Mehta J, Mehta P. Role of blood platelets and prostaglandins in coronary artery disease. Am J Cardiol 1981; 48: 366-373.

  2. Harker L. Platelets and vascular thrombosis. N Engl J Med 1994; 330: 1006-1007.

  3. Furie B, Furie BC. Molecular and cellular biology of blood coagulation. N Engl J Med 1992; 326: 800-806.

  4. Mehta P, Mehta J. Anticoagulants. En Singh B. Cardiovascular Pharmacology and Therapeutics. New York, USA, Churchill Livingstone. 1994; 281-298.

  5. Hull R, Raskob G, Rosenbloom D et al. Heparin for 5 days as compared to 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990; 322: 1260-1264.

  6. Hull R, Raskob G, Pineo G et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-982.

  7. Throux P, Waters K, Lam J et al. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992; 327: 141-146.

  8. Levine M, Raskob G, Landefeld C, Hirsh J. Hemorrhagic complications of anticoagulant treatment. Chest 1995; 108(Suppl): 276S-290S.

  9. Hirsh J, Raschke R, Warkentin T, Dalen J, Deykin D, Poller L. Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995; 108(Suppl): 258S-275S.

  10. Hirsh J, Heparin. N Engl J Med 1991; 324: 1565-1573.

  11. SCATI Group. Randomized controlled trial of subcutaneous calcium-heparin in acute myocardial infarction. Lancet 1989; 11: 182-184.

  12. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682.

  13. Gruppo Italiano per lo Studio de lla Sopravivenza nell’Infarto Miocardico. The International Study of Infarct Survival Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. Lancet 1990; 336: 71-75.

  14. Bounameaux H (editor). Low-molecular-weight heparins in prophylaxis and therapy of thromboembolic diseases. New York, USA, Marcel Dekker. 1994.

  15. Girolami A. Low molecular weight heparins in clinical practice: unsolved or partially solved problems. Arch Inst Cardiol Méx 1998; 68: 69-75.

  16. Maraganore J. Thrombin, thrombin inhibitors, and the arterial thrombotic process. Thromb Haemost 1993; 70: 208-211.

  17. Weitz J, Califf R, Ginsberg J, Hirsh J, Th‚roux P. New antithrombotics. Chest 1995; 108(Suppl): 471S-485S.

  18. Van den Boss A, Deckers J, Heyndrickx G et al. Safety and efficacy of recombinant hirudin (CGP 39393) versus heparin in patients with stable angina undergoing coronary angioplasty. Circulation 1993; 88: 2058-2066.

  19. Lee VV. Investigators TIMI-6. Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the TIMI-6 trial. Am J Cardiol 1995; 95: 7-13.

  20. Cannon C, Braunwald E. Hirudin: Initial results in acute myocardial infarction, unstable angina and angioplasty. J Am Coll Cardiol 1995; 25(Suppl): 30S-37S.

  21. Antman EM. Investigators TIMI 9A. Hirudin in acute myocardial infarction. Safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial. Circulation 1994; 90: 1624-1630.

  22. Investigators GUSTO IIa. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994; 90: 1631-1637.

  23. HIT III Investigators. Hirudin in thrombolysis III trial. Circulation 1994; 90: 1638-1642.

  24. Investigators GUSTO IIb. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335: 775-782.

  25. White HD, Aylward PE, Frey MJ, Adgey AJ, Nair R, Hillis W et al. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation 1997; 96: 2155-2161.

  26. Hirsh J, Dalen J, Deykin D, Poller L, Bussey H. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1995; 108(Suppl): 231S-246S.

  27. Wells P, Holbrook A, Crowther N, Hirsh J. Interactions of warfarin with drugs and food. Ann Intern Med 1994; 121: 676-683.

  28. Wetiz JI, Hirsh J. New antithrombotic agents. Chest 1998; 114: 715S-727S.

  29. O’Donnell C, Ridker P, Hebert P, Hennekens C. Antithrombotic therapy for acute myocardial infarction. J Am Coll Cardiol 1995; 25(Suppl): 23S-29S.

  30. Hyers T, Hull R, Weg J. Antithrombotic therapy for venous thromboembolic disease. Chest 1995; 108(Suppl): 335S-351S.

  31. Caims J, Lewis J, Meade T, Sutton G, Theroux P. Antithrombotic agents in coronary artery disease. Chest 1995; 108(Suppl): 380S-400S.

  32. Laupacis A, Albers G, Dalen J et al. Antithrombotic therapy in atrial fibrillation. Chest 1995; 108(Suppl): 352S-359S.

  33. Levine H, Pauker S, Eckman M. Antithrombotic therapy in valvular heart disease. Chest 1995; 108(Suppl): 360S-370S.

  34. Ginsberg J, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 1995; 108(Suppl): 305S-311S.




2020     |     www.medigraphic.com